MitoRx Therapeutics has strengthened its leadership team by appointing Alison Strutt as CFO, László Tankó as Consultant CMO, and Sam Fazeli as Non-Executive Director. These hires come as MitoRx prepares to advance its lead drug candidate, MTRX31, a novel small molecule targeting mitochondrial dysfunction in metabolically unhealthy obesity, into clinical development. MTRX31 has shown promising preclinical results, including significant weight loss and improved metabolic health, potentially offering a new approach to obesity treatment. The new leadership will support MitoRx’s growth and strategic efforts to bring this innovative therapy to patients at high risk of obesity-related diseases.
Imbal hasil Treasury 10 tahun AS mencapai level tertinggi sejak 2007, memicu kekhawatiran akan kerentanan di sektor perumahan, properti komersial, dan perusahaan dengan utang besar. Para ahli memperingatkan bahwa dampak terburuk akan terasa dalam 12-...
HIVE Digital Technologies, through its subsidiary BUZZ HPC, has formed a strategic partnership with ProCogia, an applied-AI and data engineering company. This collaboration will see ProCogia utilizing BUZZ HPC's Canadian data centers to provide AI so...
Axon Enterprise, a public safety technology company, has priced an offering of $1 billion in 0% convertible senior notes due 2031. The company expects to receive approximately $986 million in net proceeds, which will be used to cover the cost of capp...
Oil prices declined after a report showed an unexpected increase in U.S. crude, gasoline, and distillate inventories last week. This overshadowed concerns about potential supply disruptions following an attack on Saudi Arabia's East-West pipeline by ...
Grab mengakuisisi 60% saham Atome Financial senilai $1,49 miliar secara tunai, dengan rencana untuk membeli sisa 40% dalam waktu sekitar dua tahun. Akuisisi ini bertujuan untuk memperluas layanan keuangan Grab, khususnya di bidang pinjaman konsumen, ...
